InvestorsHub Logo
Followers 0
Posts 5690
Boards Moderated 0
Alias Born 06/09/2012

Re: me33 post# 144926

Wednesday, 09/26/2018 6:23:11 AM

Wednesday, September 26, 2018 6:23:11 AM

Post# of 426579
What’s the CEO’s personal #? I’ll call.

So the fact that two major generics players are currently still vying for entering the market with generic Vascepa in 2020 (or actually isn’t it 2019?), and AMRN’s agreement with Teva not to sell until 2029 is dependent on them NOT making it to market with their products, doesn’t bother you in the least? Those two are currently on a path to come to market. I’m sure they’re only more eager to now.

"Think for yourselves and let others enjoy the privilege to do so, too."

-Voltaire

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News